Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2003
05/29/2003US20030100769 Such s 2-(6-chloro-3-pyridyl)-2-imidazoline which has good affinity for and activate alpha-4-beta-2-nicotinic acetyl-choline receptors; for treatment and prevention of neuro-degenerative disorders (Alzheimer's/Parkinson's disease)
05/29/2003US20030100611 Delivery of gabapentin in a gastric retained dosage form for the treatment of epilepsy and other diseases
05/29/2003US20030100608 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/29/2003US20030100607 Thiolalkyl benzoic acid derivatives
05/29/2003US20030100603 Administering to the patient subject to a C-reactive protein associated inflammatory condition, an effective amount of a non-alpha-tocopherol enriched tocopherol
05/29/2003US20030100599 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands
05/29/2003US20030100598 Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl
05/29/2003US20030100596 Arylsulphonyl substituted-tetrahydro- and hexahydro-carbazoles
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100588 Indole-type inhibitors of p38 kinase
05/29/2003US20030100585 For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )- 3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid
05/29/2003US20030100579 Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders
05/29/2003US20030100577 Neurotrophic agents in treatment of solid tumors and vascular disease
05/29/2003US20030100575 Derivatives of barbituric and thiobarbituric acids; rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated
05/29/2003US20030100574 Tricyclic 3,4-propinoperhydropurines; uses thereof for blocking neuronal transmission
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders
05/29/2003US20030100561 Treatment of insulin resistance with growth hormone secretagogues
05/29/2003US20030100556 Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders
05/29/2003US20030100548 Antiarthritic agents; atherosclerosis and chronic obstructive pulmonary disease treatments
05/29/2003US20030100545 Psychological disorder treatments that increase the activity of cholinergic receptors
05/29/2003US20030100542 5-hydroxysapogenin derivatives with anti-dementia activity
05/29/2003US20030100539 Metabotropic glutamate receptors (mGluR); treating fragile X, autism, mental retardation, schizophrenia and Down's Syndrome
05/29/2003US20030100516 Analgesic agent
05/29/2003US20030100507 Administering to a mammal therapeutically effective amount of opiate analgesic and endothelin antagonist for therapy and prophylaxis of pain
05/29/2003US20030100503 Neurogenic compositions and methods
05/29/2003US20030100494 Containing growth hormone secretion promoting substance for prophylaxis and therapy of diseases involving degeneration or death of nerve cells
05/29/2003US20030100490 For therapy of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus
05/29/2003US20030100018 Mass-based encoding and qualitative analysis of combinatorial libraries
05/29/2003US20030100016 Complement C3 precursor biopolymer markers predictive of Alzheimers disease
05/29/2003US20030100015 Protein biopolymer markers indicative of age matched control
05/29/2003US20030100011 IG lambda biopolymer markers predictive of alzheimers disease
05/29/2003US20030100009 Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance
05/29/2003US20030099978 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
05/29/2003US20030099756 Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
05/29/2003US20030099725 For therapy and prophylaxis of cancers especially cancer of lung, esophagus, stomach, oral cavity and prostate as well as for therapy of Helicobacter pylori infection; useful as adjuncts to conventional surgery or radiotherapy
05/29/2003US20030099704 Controlled release oxycodone compositions
05/29/2003US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers
05/29/2003US20030099661 Compositions and methods for the treatment of immune related diseases
05/29/2003US20030099635 Use of oral gammaglobulin for the treatment of immune-mediated diseases
05/28/2003EP1314980A2 A system for cell-based screening
05/28/2003EP1314728A1 Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives
05/28/2003EP1314723A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1314719A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
05/28/2003EP1314426A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1314039A2 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type
05/28/2003EP1313857A2 Lipid metabolism molecules
05/28/2003EP1313854A2 Transporters and ion channels
05/28/2003EP1313853A2 Modulation of fas and fasl expression
05/28/2003EP1313840A2 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof
05/28/2003EP1313769A2 Antibodies to human il-1 beta
05/28/2003EP1313768A2 Antisense oligonucleotides against vr1
05/28/2003EP1313767A2 Peptide with effects on cerebral health
05/28/2003EP1313742A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
05/28/2003EP1313733A1 Pyrazolopyridine compound and pharmaceutical use thereof
05/28/2003EP1313721A2 Non-imidazole aryloxyalkylamines as h3 receptor ligands
05/28/2003EP1313720A1 N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
05/28/2003EP1313718A2 Inhibitors of copper-containing amine oxidases
05/28/2003EP1313713A2 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
05/28/2003EP1313711A2 Indazole derivatives as jnk inhibitors
05/28/2003EP1313710A1 Pyrazole derivatives and their use as protein kinase inhibitors
05/28/2003EP1313707A1 Quinoline derivatives as anti-inflammation agents
05/28/2003EP1313703A1 Prodrugs to nmda receptor ligands
05/28/2003EP1313701A1 Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
05/28/2003EP1313700A1 10-aryl-11h-benzo[b]fluorene derivatives and analogs as estrogenic compounds
05/28/2003EP1313699A1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
05/28/2003EP1313510A2 Novel pharmaceutical composition
05/28/2003EP1313499A1 Method for treating the central nervous system by administration of igf structural analogs
05/28/2003EP1313496A1 Use of a composition comprising an extract of pollen for the treatment of edema
05/28/2003EP1313495A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders
05/28/2003EP1313494A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain
05/28/2003EP1313493A1 Use of a composition comprising an extract of pollen for the treatment of irritability
05/28/2003EP1313492A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria
05/28/2003EP1313485A2 Use of an aldosterone receptor antagonist to improve cognitive function
05/28/2003EP1313483A2 Methods for inducing apolipoprotein e secretion
05/28/2003EP1313481A1 Pharmaceutical composition comprising condensed indole compound
05/28/2003EP1313478A2 Method for treatment of migraine using pde5 inhibitors
05/28/2003EP1313476A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets
05/28/2003EP1313474A2 Paroxetine compositions and processes for making the same
05/28/2003EP1313472A1 Method for reducing or eliminating smoking
05/28/2003EP1313470A1 Novel alicyclic imidazoles as h 3 agents
05/28/2003EP1313468A2 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
05/28/2003EP1313467A2 Novel pharmaceutical composition for administering n-0923
05/28/2003EP1313461A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
05/28/2003EP1313460A2 Therapeutic use and formulation of (-)-tramadol
05/28/2003EP1313457A1 Transdermal therapeutic system for releasing venlafaxine
05/28/2003EP1313456A2 Intradermal-penetration agents for topical local anesthetic administration
05/28/2003EP1313450A1 A method of treating a systemic disease
05/28/2003EP1313426A4 Succinoylamino benzodiazepines as inhibitors of a-beta protein production
05/28/2003EP1313426A2 Succinoylamino benzodiazepines as inhibitors of a-beta protein production
05/28/2003EP1163239B1 Modified amino-acid amides as cgrp antagonists
05/28/2003EP1150664B1 Novel use of orexin receptor antagonists
05/28/2003EP1146885B1 Pre-conditioning against cell death
05/28/2003EP1146865B1 Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol
05/28/2003EP1068198B1 5-heteroaryl substituted indoles
05/28/2003EP1065205B1 Heteroaromatic derivatives
05/28/2003EP1014996B1 Saccharide-containing compositions for treating alzheimer's disease and other amyloidoses
05/28/2003EP0973763B1 Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
1 ... 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 ... 1833